An optimized inexpensive emollient mixture improves barrier repair in murine skin by Man, G et al.
 Man, G; Cheung, C; Crumrine, D; Hupe, M; Hill, Z; Man, M-Q; Elias, PM; (2015) An optimized 
inexpensive emollient mixture improves barrier repair in murine skin. DERMATOLOGICA SINICA , 33 (2) 
pp. 96-102. 10.1016/j.dsi.2015.03.010. Downloaded from UCL Dsicovery: 
http://disocvery.ucl.ac.uk/1471151 
ARTICLE 
An Optimized Inexpensive Emollient Mixture Improves Barrier Repair 
in Murine Skin 
George Man1, Carolyn Cheung, BA1, Debbie Crumrine, BA1, Melanie Hupe, BA1, Zelee Hill, 
PhD2, Mao-Qiang Man, MD1,  Peter M. Elias, MD1 
1Dermatology Service, Veterans Affairs Medical Center, and Department of Dermatology, 
University of California San Francisco, CA, USA; 2Institute for Global Health, Faculty of 
Population Health Sciences, University College London, London, the United Kingdom. 
Address Correspondence To: 
Mao-Qiang Man, MD 
Dermatology (190) 
4150 Clement Street 
San Francisco, CA 94121 
USA 
Tel: (415)750-2091 
Fax: (415)750-2106 
E Mail: mqman@hotmail.com 
 
Abstract 
Maintenance of epidermal permeability barrier homeostasis is the most crucial cutaneous 
function, as it allows life in a terrestrial environment. Defective epidermal permeability barrier 
results not only in excessive water loss, but also in the induction of cutaneous inflammation and 
an increased risk of infections. Together these could help explain the increased risk of death in 
premature and low birth weight infants whose skin is functionally compromised. Improvement of 
permeability barrier function by topical barrier repair therapies could become a valuable 
approach to reduce neonatal mortality, and to prevent/treat dermatoses, accompanied by barrier 
abnormalities, and to prevent microbial pathogen colonization/invasion. Yet, the current barrier 
enhancing products are not optimal. In the present study, we optimized the ratio of several 
inexpensive ingredients, previously shown to be effective individually for barrier homeostasis, 
and then assessed the efficacy of this mixture, as well as its mechanisms of action in normal 
murine skin. Although basal barrier function, skin surface pH and stratum corneum hydration 
remained unchanged, our results show that pretreatment of normal murine skin with this 
optimized mixture accelerates barrier recovery. The barrier-enhancing effects and potent 
antimicrobial activities of this optimized mixture could be attributed at least in part to a parallel 
stimulation of epidermal differentiation and antimicrobial peptide expression.  Since the 
individual ingredients in this mixture are inexpensive, this optimized mixture show promise as a 
means of reducing neonatal mortality in low-income settings, but it also could be more widely 
used to prevent skin disorders associated with epidermal permeability barrier abnormalities. 
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Introduction 
Mortality rates for pre-term (<37 weeks gestational age) and low birth weight infants (<2500g), 
are higher than for their term and normal birth weight counterparts1. This is particularly true in 
low income countries. For example, world-wide, more than 60% of preterm births occur in Africa 
and South Asia2, and neonatal deaths accounts for 50% of the infant mortality rate in Africa and 
other low income countries3,4.  Although neonatal mortality rates have been declining recently, 
declines are slower than for older children and efforts to decrease neonatal mortality rates are a 
global priority5. Improving the care of small neonates has been identified as one of the 
interventions likely to have the greatest impact on neonatal mortality6. 
     
Studies have found that the application of a range of emollients reduce neonatal mortality 
among preterm infants, decrease infection rates and increase weight7. The mechanisms of 
action are unclear. The benefits of emollients for reducing neonatal mortality could be attributed 
to the prevention of infection8-10, it could also be due to the improvement of epidermal 
permeability barrier. This hypothesis is supported by a negative correlation that has been found 
between transepidermal water loss (TEWL), an indicator of epidermal permeability barrier, with 
both birth weight11 and gestational age12-14, and the higher neonatal mortality rates found in 
male compared to female neonates15, the latter exhibiting superior barrier function16.  
Additionally, it is known that compromised permeability barrier increases the risk of infections17, 
and increases the loss of body fluid and body weight18,19. It also increases energy consumption 
in preterm infants18. Given the findings that topical emollients reduce systemic infections and 
neonatal mortality in preterm infants5,9,20, and the likelihood that this is due to enhanced 
epidermal permeability barrier, products to improve epidermal permeability represent an 
effective strategy to reduce neonatal mortality rates, particularly in preterm and low birth weight 
infants, living in low income countries.  
Some products are already available to improve epidermal permeability, including sunflower oil 
and Aquaphor8,13. Topical applications of these barrier enhancing products has been shown to 
reduce mortality rates by 26-32% in preterm infants21. Although sunflower seed oil is effective, 
its lipid composition, a key determinant of its efficacy, varies with the source of the oil. Moreover, 
the high proportion of fatty acids in this and other oils can disturb the normal ratio of lipids in 
stratum corneum, resulting in disruption of permeability barrier and skin irritation22. Aquaphor 
and petrolatum can instantly lower TEWL due to their occlusive properties, but occlusion can 
inhibit endogenous restoration of natural permeability barrier23. Other physiologic lipid-based 
products, such as Epiceram®, are also effective in improving barrier function, but their costly 
ingredients render them unaffordable in many developing countries.  In the present study, we 
optimized ratios of several inexpensive ingredients, each of which was shown previously to 
improve barrier function individually24,25, and evaluated the effects of this optimized mixture on 
epidermal permeability barrier homeostasis in normal murine skin, as well as, the mechanistic 
basis of its benefits. 
Materials and Methods 
Materials: 6-8 weeks old female albino hairless (SKH1) mice were purchased from Charles 
River Laboratories (Wilmington, MA). Ethanol and propylene glycol were purchased from Fisher 
Scientific (Fairlane, NJ). The optimized mixture, containing sunflower oil, glycerol, borage oil, 
petrolatum and lanolin, was prepared in-house and vertexed prior to topical application. 
Epiceram, a product known to improve barrier function in atopic dermatitis26-28, from PuraCap 
was used as positive control. Affinity-purified, rabbit anti-mouse antibodies to filaggrin, involucrin, 
and loricrin was purchased from BabCo (Richmond, CA). Anti-mouse cathelin-related 
antimicrobial peptide (CAMP) antibody was from Santa Cruz Biotechnology (Texas, USA). 
Secondary biotinylated goat anti-rabbit IgG and ABC-peroxidase kit were purchased from 
Vector laboratories (Burlingame, CA, USA). The anti-proliferating cell nuclear antigen (PCNA, 
Ki-67) was purchased from CalTag Laboratories (Burlingame, CA, USA). 
 
Experimental protocols and functional studies: All animal procedures were approved by the 
Animal Studies Subcommittee (IACUC) of the San Francisco Veterans Administration Medical 
Center and performed in accordance with their guidelines. Mice were maintained in a 
temperature- and humidity-controlled room, and given standard laboratory food and tap water 
ad libitum. To determine whether repeatedly topical applications of the optimized mixture 
improve epidermal function in normal mouse skin, mice were topically treated with the optimized 
mixture twice daily for three days. Untreated mice served as normal controls, and mice treated 
with Epiceram served as positive controls. Basal epidermal biophysical properties were 
assessed by measuring transepidermal water loss (TEWL) and stratum corneum hydration 
using respective probes (TM300 for TEWL and CM825 for hydration) connected to MPA5 (C&K, 
Cologne, Germany).  pH900 (C&K, Cologne, Germany) was used to measure skin surface pH.  
For barrier recovery, TEWL was measured at 0 and 2 hours after tape stripping, which result in 
a 10-fold increase in TEWL, and percent barrier recovery rates were calculated as described 
previously29. To determine whether single application of the optimized mixture improve 
epidermal function in barrier-damaged mouse skin, mice were tape-stripped and immediately 
followed by topical application of either the optimized mixture or Epidceram. Tape-stripped mice 
left air exposure served as controls. TEWL was measured at 0, 1 and 5 hours after tape 
stripping. The results were normalized by untreated controls, setting the untreated controls as 
100%. 
Immunohistochemistry: The methods for assessment of both the differentiation markers and 
proliferation were carried out as published previously30,31.  Briefly, after deparaffinization and 
blocking with 4% bovine serum albumin, 5m paraffin sections were incubated with primary 
rabbit anti-mouse antibodies (Covance/BabCo. Berkeley, CA) at the dilutions of 1:2000 for 
filaggrin, 1:1000 for involucrin, and 1:500 for loricrin, overnight at 4C.  After washing with 10mM 
citrate buffer, sections were incubated with goat anti-rabbit antibody (1:400) for 30 min at room 
temperature, followed by ABC-peroxidase (Vector, Burlingame, CA) reaction.  For PCNA 
staining, sections were incubated with biotinylated monoclonal anti-PCNA antibody (CalTag 
Laboratories, Burlingame, CA) for 2 hours at room temperature. The sections were visualized 
with a Zeiss (Axioplan 2) microscope (Jena, Germany).  Digital images were captured with 
AxioVision software 2.05 (Carl Zeiss Vision, Munich, Germany).  
Electron Microscopy: Skin biopsies from vehicle- and antagonist-treated mice (as above) were 
fixed in Karnovsky’s fixative overnight, and post-fixed with either 0.25% ruthenium tetroxide or 
1% aqueous osmium tetroxide, containing 1.5% potassium ferrocyanide, as described 
previously31,32. Ultrathin sections were examined using an electron microscope (Zeiss 10A, Carl 
Zeiss, Thornwood, NY) operated at 60 kV. 
Statistical Analyses: Data are expressed as the means + SEM.  Unpaired two-tailed student t 
test with Welch’s correction was used to determine significant differences when two groups 
were compared.  
Results 
Optimized mixture accelerates permeability barrier recovery 
After three days of the treatment with the optimized mixture, the overall gross appearance of 
skin was similar between treated and untreated mice. Inflammation was not evident 
histologically, nor was epidermal proliferation abnormal, as assessed by H&E and PCNA 
staining, respectively, (data not shown). We then assessed the impact of this optimized mixture 
on epidermal biophysical properties in normal skin. As shown in Figure 1A, pretreatment with 
the mixture did not alter basal biophysical properties in normal murine skin. In contrast, 
permeability barrier recovery significantly accelerated 2 hours after barrier disruption, as 
compared with untreated controls. Surprisingly, repeated topical applications of Epiceram, a 
known barrier enhancer, elevated baseline TEWL and delayed barrier repair, in comparison to 
either untreated control or the optimized mixture treatment (Fig 1A).  
Since epidermal permeability barrier is compromised in both preterm and low birth weight 
infants, we next determined whether this 
optimized mixture improves epidermal 
permeability barrier in skin with perturbed barrier. 
Our results showed that a single topical 
application of either the optimized mixture or 
Epiceram significantly reduced TEWL one hour 
after barrier disruption (Figure 1B). But no 
differences were seen by 5 hours after application. 
These results demonstrate that topical application 
of the optimized mixture improves epidermal 
permeability homeostasis in both normal and 
perturbed skin. 
Topical optimized mixture stimulates 
epidermal differentiation 
Because epidermal differentiation-related proteins are key determinants for epidermal 
permeability barrier33, we next determined whether the topical optimized mixture upregulates the 
expression of epidermal differentiation-related proteins, which provide a mechanism whereby 
this mixture improves 
permeability barrier 
homeostasis. Indeed, the 
intensity of immunostaining for 
involucrin was markedly 
enhanced following 3days of 
treatment with either the 
topical optimized mixture or 
Epiceram (Fig 2e, f vs. 2d), 
while the intensity of epidermal 
filaggrin (Fig 2a vs. 2b,c) 
staining remained unchanged. 
The optimized mixture did not 
alter the expression of loricrin 
while a slight reduction in 
loricrin expression was evident 
following Epiceram applications. 
These result s suggest that 
topical optimized mixture could 
improve barrier function in part 
by upregulation of epidermal 
involucrin expression. 
Topical optimized mixture 
stimulates lamellar body 
formation  
Since formation of both the 
permeability and antimicrobial barrier requires secretion of lamellar body content34, we next 
assessed the changes in lamellar body formation following 3days of topical treatments with 
optimized mixture. As seen in Figure 3B, more lamellar bodies are present in the cytosol of the 
stratum granulosum following topical treatment with the optimized mixture in comparison to 
untreated skin (Figure 3A).   Moreover, acceleration of membrane bilayer maturation became 
evident in optimized mixture-treated skin (arrows in Figure 3D) in comparison to untreated skin 
(arrows in Figure 3C). These results suggest that the optimized mixture-induced enhancement 
of epidermal permeability barrier homeostasis can be attributed, at least in part, to stimulation of 
lamellar body formation and accelerated membrane bilayer maturation. 
 
Topical optimized mixture upregulates the expression of epidermal antimicrobial peptide 
 Previous studies have demonstrated that epidermal antimicrobial peptides such as CAMP not 
only provide a barrier against infection, but also are crucial for permeability barrier. Moreover, 
the expression levels of CAMP are lower in preterm infants than in full term babies35. Thus, we 
next assessed whether enhanced expression of epidermal CAMP occurs after the treatment 
with the optimized mixture, providing an additional, potential mechanism for the improvement of 
barrier and further providing the rational for clinical usage in treating preterm infants. As shown 
in Figure 4, a dramatic increase in the intensity of CAMP immunostaining became evident 
following treatment with both optimized mixture and Epiceram for 3 days in comparison with 
untreated controls (Fig 4A vs. 4B & C). These results demonstrate that the topical optimized 
mixture enhances the expression of a key epidermal antimicrobial peptide, i.e., CAMP.  
Discussion 
Previous studies have shown that improving epidermal permeability barrier through topical 
applications of emollients reduces neonatal mortality rates in preterm infants21,36, increases 
body weight7, prevents systemic infection37, and delays the development of atopic dermatitis38. 
Although emollients such as sunflower oil and Aquaphor show promise as a means of improving 
barrier function8 , they still have certain limitations. For example, fatty acid (a key determinant for 
permeability barrier) composition in sunflower oil varies with the sources, consequently affecting 
its clinical efficacy.  Aquaphor can improve permeability barrier, but with no benefits for the 
reduction of infection risk10 whereas both defective permeability barrier and infection are the risk 
factors for neonatal deaths. Therefore, development of the products benefiting both permeability 
and antimicrobial barrier becomes imperative. In the present study, we developed an optimized 
mixture that improves epidermal permeability barrier in both intact and barrier-damaged skin. 
The underlying mechanisms by which this optimized mixture improves epidermal permeability 
barrier include stimulation of epidermal differentiation, upregulation of epidermal antimicrobial 
peptide expression, and increased lamellar body formation. Epidermal differentiation-related 
proteins are critical components of “bricks” of the straum corneum, providing a scaffold 
necessary for the post-secretory organization of extracellular lipids33,39.  Pertinently, deficiency 
of either filaggrin or involucrin compromises epidermal permeability barrier 40,41. Here, we show 
that topical applications of the optimized mixture dramatically increase the expression of 
involucrin.  In addition, epidermal antimicrobial peptides provide not only an antimicrobial barrier, 
but also contribute to permeability barrier42. We showed previously that CAMP deficiency delays 
permeability barrier recovery in mice42. Thus, upregulation of epidermal CAMP expression could 
be another potential mechanism for the improved barrier function in skin treated with the 
optimized mixture.   
Lamellar bodies in stratum granulosum are the only known organelles that deliver lipids and 
CAMP to the stratum corneum interstices42,43.  Maturation of membrane bilayers is required for 
the formation of a competent permeability barrier. In the present study, increased number of 
lamellar body and acceleration of membrane bilayer maturation become evident in skin treated 
with the optimized mixture, providing an additional mechanism by which the optimized mixture 
could improve permeability barrier function.  All these changes in epidermal function, induced by 
the optimized mixture, are likely mediated by peroxisome proliferator-activated receptor 
(PPARs), because both the borage oil and sunflower seed oil in the mixture, contain linoleic acid 
and -linoleic acid, PPARγ activators. Activation of PPARγ stimulates epidermal differentiation, 
and lamellar body formation and secretion.  In particularly, PPARγ is required for 1 , 25-
dihydroxyvitamin D3-induced involucrin expression44.  Likewise, PPARγ also mediates 1a, 25-
dihydroxyvitamin D3-induced hBD-3 and cathelicidin expression in keratinocytes45,46. The 
putative mechanisms whereby this optimized mixture improves epidermal permeability barrier 
are illustrated in Figure 5.  
It is worth noting that the novelty of this mixture is that all the ingredients are needed for optimal 
efficacy, thereby eliminating additional ingredients, that would increase cost and potentially 
cause adverse effects. For example, all ingredients in this mixture can increase stratum 
corneum hydration, which are required to improve in certain skin disorders, such as atopic 
dermatitis, psoriasis, ichthyosis and aged skin. Lower concentrations of petrolatum and lanolin 
instantly reduce TEWL without producing excessively occlusive effect, which could potentially 
harm skin defense responses to external insults. These two ingredients are particularly useful 
for correcting barrier function in barrier-
damaged skin. Moreover, lower 
concentrations of sunflower oil and 
borage oil reduce greasiness and 
potential irritant effects without sacrificing 
benefits. Although there is no clinical data 
to ascertain the efficacy of this optimized 
mixture in humans, the following 
beneficial effects of the optimized mixture 
on epidermal function still provide a strong 
rationale for its clinical applications. 
1. Accelerating barrier repair without 
altering basal barrier function: Optimal 
permeability barrier is required for 
epidermal homeostasis. A supper protection such as occlusive products can reduce TEWL, 
but also inhibit cellular metabolism. Of course, compromised barrier causes skin diseases. 
This optimized mixture maintains barrier function at its normal level while accelerating 
barrier repair upon requirement (barrier disruption). Therefore, this mixture could serve as a 
skin emergency kit and could be routinely applied to normal skin.  The barrier could be 
quickly repaired on once barrier gets damaged such as in aged skin where barrier recovery 
is delayed.  
2. Improving barrier in barrier damaged skin: Barrier disruption not only stimulates epidermal 
proliferation and induces inflammation, but also facilitates bacteria invasion and allergen 
penetration.  Thus, this mixture could be very useful for the prevention of inflammation and 
infection in barrier damaged skin such as infants, particularly premature infants who 
predispose to skin infection. 
3. Upregulating epidermal antimicrobial peptide expression: In addition to impact on 
permeability barrier function, epidermal antimicrobial peptides play a key role against 
microbial infection.  The infants, especially premature infants, are more vulnerable to 
bacterial infection, largely due to premature innate immunity. And infection is among the 
major causes of infant mortality.  Moreover, both atopic dermatitis and ichthyosis are at 
higher risk for certain types of infection. Since this optimized mixture can upregulate 
epidermal antimicrobial peptide expression and improve barrier function, it could be useful 
for infants and other dermatoses. 
 
Conclusions 
Because this inexpensive formulation improves epidermal permeability barrier function and 
antimicrobial defense, it could be useful for the treatment of neonatal and aged skin, as well as 
inflammatory dermatoses characterized by barrier abnormalities. 
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Figure Legends 
Figure 1. Topical optimized mixture improves epidermal permeability barrier homeostasis. 
Mice were treated as described in materials and method section. Fig 1A depicts the influences 
of topical optimized mixture and Epiceram on statum corneum biophysical properties after 3 
days of treatment. . Fig 1B displays the effects of topical optimized mixture and Epiceram on 
permeability barrier homeostasis after a single application to barrier disrupted murine skin. 
Results were normalized by untreated controls as shown by dotted line. N and significances are 
indicated in the figures. 
Figure 2. Topical optimized mixture stimulates epidermal differentiation. After 3 days of 
treatments with either topical optimized mixture or Epiceram, skin samples were taken for 
immunohistochemical staining of differentiation marker proteins.  Figures 2a,d, g are untreated 
normal controls; Figures 2b,e,h are Epiceram-treated skin, and 2c,f,i are optimized mixture-
treated skin. Magnification bar=50 m. 
Figure 3. Topical optimized mixture stimulates lamellar body formation. After 3 days of 
treatments，skin biopsies were taken for ultrastructural analysis. Figures 3A & B represent 
lamellar bodies, as indicated by arrows, in untreated and optimized mixture-treated, respectively. 
Figures 3C & D display lipid processing (see arrow) in untreated and optimized mixture-treated, 
respectively. Magnifications for Figures 3A & B are the same and magnification bar =1 m;  
Magnifications for Figures 3C & D are the same and magnification bar =0.5 m.   
Figure 4. Topical optimized mixture upregulates the expression of epidermal 
antimicrobial peptide. After 3 days of treatments with either topical optimized mixture or 
Epiceram, skin samples were taken for immunohistochemical staining of CAMP.  Figures 4a,b, 
and c are untreated normal control-, Epiceram- and optimized mixture-treated, respectively. All 
pictures were taken at the same magnification. Magnification bar=40 m. 
Figure 5. The putative mechanisms by which topical optimized mixture improves 
permeability barrier homeostasis.  
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